Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.84 +0.62 (+1.41%)
Streaming Delayed Price Updated: 1:12 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share... 
Via StockStory
News headline image
Royalty Pharma Reports First Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Peering Into Royalty Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors ↗
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors 
Via Chartmill
News headline image
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations. ↗
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
News headline image
3 Mid-Cap Stocks Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Topics Economy
News headline image
Royalty Pharma Declares Second Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,... 
Via StockStory
Topics Economy Government World Trade
News headline image
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
News headline image
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
4 Healthcare Stocks With Massive Gains—and More to Come
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
News headline image
Royalty Pharma Announces Upcoming Investor Day
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Reasons to Sell RPRX and 1 Stock to Buy Instead
Over the past six months, Royalty Pharma has been a great trade. While the S&P 500 was flat, the stock price has climbed by 17.3% to $33.06 per share. This performance may have investors wondering how... 
Via StockStory
Topics Stocks
News headline image
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Uncovering Noteworthy Technical Analysis Findings for ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX). ↗
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
News headline image
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Value Stocks in Hot Water
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
How Do Investors Really Feel About Royalty Pharma? ↗
 
Via Benzinga
News headline image
Is ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range? ↗
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout. 
Via Chartmill
News headline image
1 Stock Under $50 with Exciting Potential and 2 to Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma. 
Via Benzinga
News headline image
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday? ↗
U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.